These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3571042)

  • 1. In-vitro activity of two new quinolone antimicrobial agents, S-25930 and S-25932 compared with that of other agents.
    Neu HC; Chin NX
    J Antimicrob Chemother; 1987 Feb; 19(2):175-85. PubMed ID: 3571042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial activity of amifloxacin (WIN 49, 375), a new quinolone agent.
    Neu HC; Labthavikul P
    Diagn Microbiol Infect Dis; 1985 Nov; 3(6):469-78. PubMed ID: 4064609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of temafloxacin, a new difluoro quinolone antimicrobial agent.
    Chin NX; Figueredo VM; Novelli A; Neu HC
    Eur J Clin Microbiol Infect Dis; 1988 Feb; 7(1):58-63. PubMed ID: 3132380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative activity of fleroxacin, three other quinolones and eight unrelated antimicrobial agents.
    McCarter YS; Mazens-Sullivan MF; Bartlett RC
    Chemotherapy; 1992; 38(5):308-18. PubMed ID: 1337507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro activity of ofloxacin, a quinolone carboxylic acid compared to other quinolones and other antimicrobial agents.
    Kumada T; Neu HC
    J Antimicrob Chemother; 1985 Nov; 16(5):563-74. PubMed ID: 3865923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro selection of bacteria resistant to the 4-quinolone agents.
    Limb DI; Dabbs DJ; Spencer RC
    J Antimicrob Chemother; 1987 Jan; 19(1):65-71. PubMed ID: 3470281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of two new aryl-fluoroquinolone antimicrobial agents, difloxacin (A-56619) and A-56620 compared to that of other antimicrobial agents.
    Hirschhorn L; Neu HC
    Chemotherapy; 1987; 33(1):28-39. PubMed ID: 3549179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates.
    Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C
    Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro activity of a new fluorinated 4-quinolone, QA-241.
    Niu WW; Neu HC
    Diagn Microbiol Infect Dis; 1989; 12(3):243-51. PubMed ID: 2791486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
    Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of trovafloxacin (CP 99,219), a new fluoroquinolone against hospital isolates.
    Ling TK; Liu EY; Cheng AF
    Chemotherapy; 1999; 45(1):22-7. PubMed ID: 9876206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
    Pillar CM; Aranza MK; Shah D; Sahm DF
    J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The North American component (the United States and Canada) of an International Comparative MIC trial monitoring ofloxacin resistance.
    Hoban DJ; Jones RN; Harrell LJ; Knudson M; Sewell D
    Diagn Microbiol Infect Dis; 1993; 17(2):157-61. PubMed ID: 8243037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of CI-934, a new quinolone, compared with that of other quinolones and other antimicrobial agents.
    Mandell W; Neu HC
    Antimicrob Agents Chemother; 1986 May; 29(5):852-7. PubMed ID: 3729343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative antimicrobial activity of lomefloxacin, norfloxacin, ofloxacin, ciprofloxacin and enoxacin against > 500 bacterial isolates.
    Ismaeel NA; Tayeb OS
    Microbios; 1993; 74(300):147-54. PubMed ID: 8396196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The sensitivity of gram-negative and gram-positive bacteria to ofloxacin.
    Speciale A; Stefani S; Caccamo F; Nicolosi VM; Nicoletti G
    Drugs Exp Clin Res; 1987; 13(9):555-61. PubMed ID: 3480796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activity of imipenem against 1386 clinical isolates.
    Belobraydic KA; Qadri SM
    Methods Find Exp Clin Pharmacol; 1986 Nov; 8(11):675-8. PubMed ID: 3468319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.